Centrosome dysfunction and autophagy dysregulation in renal cell carcinoma: Implications for tumor progression and...

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Renal cell carcinoma (RCC) is a complex kidney cancer with genetic and metabolic drivers.
• Centrosome dysfunction and autophagy dysregulation are increasingly implicated in RCC development and treatment resistance.
• The transcription factors TFEB/TFE3 are known regulators of autophagy and lysosomal biogenesis.

Purpose of the Study:

• To explore the mechanistic crosstalk between centrosome dysfunction and autophagy in RCC.
• To focus on MiT family translocation RCC and the role of TFEB/TFE3.
• To discuss emerging therapeutic strategies targeting these interconnected pathways.

Main Methods:

• Literature review of current research on centrosome function, autophagy, and TFEB/TFE3 in RCC.
• Analysis of molecular mechanisms linking centrosome status and autophagy.
• Synthesis of findings to identify therapeutic opportunities.

Main Results:

• Centrosome dysfunction contributes to genomic instability in RCC.
• Autophagy plays a dual role in RCC, acting as a tumor suppressor early on and promoting survival in advanced stages.
• TFEB/TFE3 mediate a functional link between centrosome abnormalities and autophagy, influencing RCC progression and therapy resistance.

Conclusions:

• The interplay between centrosome dysfunction and autophagy, mediated by TFEB/TFE3, is crucial in RCC pathogenesis.
• Targeting the TFEB/TFE3-autophagy-centrosome axis presents a promising therapeutic avenue for RCC, particularly MiT family translocation RCC.
• Further research into these mechanisms could lead to novel treatment strategies for kidney cancer.